ClinicalTrials.gg
TerminatedNCT02479204Updated Sep 22, 2025

Clinical Study to Investigate Safety and Effects on Heart Rate, Blood Pressure, and Pharmacokinetic Interactions of ACT-334441

A Phase 1 interventional study of ACT-334441 2 mg and ACT-334441 4 mg in Healthy Subjects, sponsored by Viatris Innovation GmbH. Terminated at 1 site in France. Open to participants aged 25 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-22.

Sponsored by Viatris Innovation GmbH (part of Viatris Inc.) · Phase 1, Interventional, and Other

Why this study was terminated
Based on results from the pilot phase, the study is terminated. No safety events leading to discontinuation were reported

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
10
Allocation
Randomized
Ages
25 Years to 55 Years
Sex
All
01

Study summary

The aim of the study is to investigate the safety of the concomitant administration of ACT-334441 with cardiovascular drugs.

Read the detailed description

The study will consist of two parts: a pilot part (Part A) that will be completed prior to the start of the main part (Part B). The Subjects who will participate in Part A are excluded from Part B.

02

Conditions studied

  • Healthy Subjects

Keywords

  • safety
  • heart rate
  • pharmacokinetics
03

In context

Lead sponsor

Viatris Innovation GmbH is the lead sponsor of 24 studies on the registry; 3 are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 3 (30%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
25 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed
  • (BMI) between 18.0 and 30.0 kg/m2 (inclusive) at screening.
  • Women of must have a negative pregnancy test and they must use reliable methods of
  • Healthy on the basis of physical examination,cardiovascular assessments and laboratory tests

Exclusion criteria

Exclusion Criteria:

  • Pregnant or lactating women
  • Any to the study drugs
  • History or presence of any disease or condition or treatment, which may put the subject at risk of participation in the study or may interfere with the absorption, distribution, metabolism or excretion of the study drugs
  • Any abnormalities in laboratory tests, vital signs, variables and pulmonary variables
  • Any circumstances or conditions, which, in the opinion of the investigator, may affect the subject's full participation in the study or compliance with the protocol
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    Part A ACT-334441 + atenolol

    4 subjects will receive 50 mg of atenolol once daily for 6 days, and a concomitant single administration of ACT-334441 2 mg on Day 6

    Drug: ACT-334441 2 mg · Drug: Atenolol

  • Experimental
    Part A ACT-334441 + diltiazem

    4 subjects will receive 240 mg of diltiazem once daily for 6 days, and a concomitant single administration of ACT-334441 2 mg on Day 6

    Drug: ACT-334441 2 mg · Drug: Diltiazem ER

  • Experimental
    Part B ACT-334441 + atenolol

    12 subjects will receive 50 mg of atenolol (once daily) from day 1 to day 15, placebo once on day 6, and ACT-334441 4 mg (once daily) from day 8 to day 15

    Drug: ACT-334441 4 mg · Drug: Placebo · Drug: Atenolol

  • Experimental
    Part B ACT-334441 + diltiazem

    12 subjects will receive 240 mg of diltiazem (once daily) from day 1 to day 15, placebo once on day 6, and ACT-334441 4 mg (once daily) from day 8 to day 15

    Drug: ACT-334441 4 mg · Drug: Placebo · Drug: Diltiazem ER

Interventions

  • capsule containing ACT-334441 at a strength of 2 mg

  • capsule containing ACT-334441 at a strength of 4 mg

  • DrugPlacebo

    ACT-33441-matching placebo

  • film-coated tablet containing atenolol at a strength of 50 mg

    Also known as: Tenormine

  • DrugDiltiazem ER

    film-coated tablet containing diltiazem at a strength of of 120 mg

    Also known as: Bi-tildiem

06

What researchers measure

Primary outcomes

  1. PR intervals measured by 12-lead ECG (Part A + Part B)

    Absolute PR intervals and corresponding changes from baseline at the different days of measurement

    Time frame: Days 1 and 6 (Part A); Days 1, 6, 8, 9, 15, and 16 (Part B)

  2. Heart rate (HR) measured by 12-lead ECG (PArt A + Part B)

    Absolute heart rates at the different days of measurement

    Time frame: Days 1 and 6 (Part A); Days 1, 6, 8, 9, 15, and 16 (Part B)

  3. Hourly mean heart rate (HR) measured by 24-hour Holter ECG

    Absolute and change from baseline in hourly mean HR on each day of measurement

    Time frame: Days 1 and 6 (Part A); Days 1, 6, 8, 9, 15, and 16 (Part B

Secondary outcomes

  1. Areas under the plasma concentration-time curves (AUC) for ACT-334441, diltiazem and atenolol (Part B)

    AUCs will be calculated will be calculated according to the linear trapezoidal rule for the following periods: from zero to time t of the last measured concentration above the limit of quantification, from zero to 24h after study drug administration, from zero to infinity)

    Time frame: Blood samples from Day 1 to Day 20 for the PK profile of diltiazem and atenolol, and from Day 8 to Day 21 for the PK profile of ACT-334441.

  2. Maximum plasma concentration (Cmax) for ACT-334441, diltiazem and atenolol (Part B)

    The measured individual concentrations of ACT-334441, diltiazem and atenolol will be used to obtain their respective Cmax

    Time frame: From Day 1 to Day 20 for diltiazem and atenolol; from Day 8 to Day 21 for ACT-33444.

  3. Time to reach the maximum plasma concentration (tmax) for ACT-334441, diltiazem and atenolol (Part B)

    The measured individual concentrations of ACT-334441, diltiazem and atenolol will be used to obtain their respective tmax

    Time frame: From Day 1 to Day 20 for diltiazem and atenolol; from Day 8 to Day 21 for ACT-33444

  4. Terminal half-life [t(1/2)] of ACT-334441, diltiazem and atenolol (Part B)

    Time required for the plasma concentration of a drug to decrease by 50% in the final stage of its elimination

    Time frame: From Day 1 to Day 20 for diltiazem and atenolol; from Day 8 to Day 21 for ACT-33444

  5. Trough plasma levels (Ctrough) of of ACT-334441, diltiazem and atenolol (Part B)

    Ctrough will be used to determine the attainment of steady state conditions

    Time frame: From Day 1 to Day 15 for diltiazem and atenolol; from Day 8 to Day 15 for ACT-33444

  6. Number of subjects with adverse events as a measure of safety

    An AE is defined as any unfavorable and unintended sign, including an abnormal laboratory finding, symptom or disease, that occurs during the course of the study, whether or not considered related to the study drug

    Time frame: From baseline to end of study [Day 20-23 (Part A), Day 556-59 (Part B)]

Other outcomes

  1. Lymphocyte count as a measure of immunomodulation (Part A + Part B)

    Time frame: Day 1, Day 6, Day 12 and Day 20 (Part A); Day 1 and Day 8 toDay 16 (Part B)

07

Study locations

1 site
  • BIOTRIAL
    Rennes, CS 34246, France
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2015 to primary completion in May 2016, 12 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 17, 2015
First posted
Jun 24, 2015
StartActual
Apr 28, 2015
Primary completionActual
May 1, 2016
CompletionActual
May 1, 2016
Last update
Sep 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02479204
Responsible party
Sponsor
First posted
Jun 24, 2015
Start date
Apr 28, 2015
Primary completion
May 1, 2016
Completion
May 1, 2016
Last update
Sep 22, 2025

Study contacts

Clinical Trials
study director · Viatris Innovation GmbH

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cenerimod · Atenolol

Start the discussion